Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate

Ruiyu Pu; James Coleman; James Coisman; Eiji Sato; Taishi Tanabe; Maki Arai; Janet K Yamamoto

doi:10.1016/j.jfms.2004.08.005

Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate

J Feline Med Surg. 2005 Feb;7(1):65-70. doi: 10.1016/j.jfms.2004.08.005.

Authors

Ruiyu Pu¹, James Coleman, James Coisman, Eiji Sato, Taishi Tanabe, Maki Arai, Janet K Yamamoto

Affiliation

¹ Department of Pathobiology, College of Veterinary Medicine, University of Florida, P.O. Box 110880, Gainesville, FL 32611-0880, USA.

PMID: 15686976
DOI: 10.1016/j.jfms.2004.08.005

Abstract

Vaccine trials were undertaken to determine whether the Fel-O-Vax FIV, a commercial dual-subtype (subtypes A and D) feline immunodeficiency virus (FIV) vaccine, is effective against a subtype B FIV isolate. Current results demonstrate the Fel-O-Vax FIV to be effective against a subtype B virus, a subtype reported to be the most common in the USA.

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review

MeSH terms

Animals
Cats
Feline Acquired Immunodeficiency Syndrome / immunology*
Feline Acquired Immunodeficiency Syndrome / prevention & control*
Immunodeficiency Virus, Feline / genetics
Immunodeficiency Virus, Feline / immunology*
Vaccines, Inactivated / immunology
Veterinary Medicine
Viral Vaccines / immunology*

Substances

Vaccines, Inactivated
Viral Vaccines

Grants and funding

R01 AI30904/AI/NIAID NIH HHS/United States